Form 4: BioXcel Therapeutics CFO Richard Steinhart Reports Stock and Option Awards

Richard Steinhart, CFO of BioXcel Therapeutics, reports the acquisition of restricted stock units and stock options.

Summary

• Richard Steinhart, the Chief Financial Officer of BioXcel Therapeutics, Inc., filed a Form 4 on April 1, 2025, reporting transactions related to the company's securities.
• On July 22, 2024, Steinhart acquired 625 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of BioXcel's common stock.
• These RSUs will vest and settle on the first anniversary of the grant date, contingent upon Steinhart's continuous employment with the company.
• Steinhart also acquired an option to purchase 1,875 shares of common stock at a price of $1.20.
• This option vests in two tranches: 50% on the first anniversary and 50% on the second anniversary of the grant date, also subject to continuous employment.
• The share amounts have been adjusted to reflect a 1-for-16 reverse stock split that took effect on February 7, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The grants themselves are generally viewed as a positive incentive, but the filing itself is simply informational.

Positives

• The grant of RSUs and stock options to the CFO could be seen as an incentive to align his interests with the long-term success of the company.
• The vesting schedules tied to continuous employment suggest a commitment from the CFO to remain with the company.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules of the RSUs and stock options suggest an expectation of continued employment and contribution from the CFO.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The granting of stock options and RSUs is a common practice to incentivize and retain key executives in the biotechnology industry.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices in the biotech industry, often used to attract and retain talent.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar equity-based compensation plans for their executives.
• The vesting schedules (one and two years) are fairly typical for such grants.

Stakeholder Impact

• Shareholders may view the equity grants as aligning management's interests with the company's performance.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates

Keywords

BioXcel Therapeutics, BTAI, Richard Steinhart, CFO, Restricted Stock Units, Stock Options, Form 4, Beneficial Ownership, Reverse Stock Split